Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 5:8:693325.
doi: 10.3389/fmolb.2021.693325. eCollection 2021.

Post-Translational Modifications Modulate Proteinopathies of TDP-43, FUS and hnRNP-A/B in Amyotrophic Lateral Sclerosis

Affiliations
Review

Post-Translational Modifications Modulate Proteinopathies of TDP-43, FUS and hnRNP-A/B in Amyotrophic Lateral Sclerosis

Stefania Farina et al. Front Mol Biosci. .

Abstract

It has been shown that protein low-sequence complexity domains (LCDs) induce liquid-liquid phase separation (LLPS), which is responsible for the formation of membrane-less organelles including P-granules, stress granules and Cajal bodies. Proteins harbouring LCDs are widely represented among RNA binding proteins often mutated in ALS. Indeed, LCDs predispose proteins to a prion-like behaviour due to their tendency to form amyloid-like structures typical of proteinopathies. Protein post-translational modifications (PTMs) can influence phase transition through two main events: i) destabilizing or augmenting multivalent interactions between phase-separating macromolecules; ii) recruiting or excluding other proteins and/or nucleic acids into/from the condensate. In this manuscript we summarize the existing evidence describing how PTM can modulate LLPS thus favouring or counteracting proteinopathies at the base of neurodegeneration in ALS.

Keywords: RNA binding proteins; amyotrophic lateral sclerosis; low-complexity domain; post-translational modifications; protein aggregations.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The domain structure of hnRNP-A1, TDP-43 and FUS. The RNA-binding proteins hnRNP-A1, TDP-43 and FUS share structure similarities. Particularly, they harbor Prion-like domain, RNA-recognition motif (RRM) and nuclear localization signal (NLS). hnRNP-A1 and FUS are both characterized by the presence of Arg-Gly-Gly-rich (RGG) domains while TDP-43 has a Gly-rich (G-rich) domain and hnRNP-A1 display a M9 motif. Moreover, both FUS and TDP-43 present nuclear export signal (NES) but only FUS has a zinc-finger (ZnF) domain and a Gln-Gly-Ser-Tyr-rich (QGSY-rich) domain.
FIGURE 2
FIGURE 2
Assembly of condensates and PTMs. Panel A. LCD-containing proteins (including TDP-43, FUS and hnRNPA1) under certain conditions assume a misfolded state in which several intra and inter-molecular interaction can be established. Different PTMs tend to stimulate or dampen the formation of insoluble condensate in which LCD-containing proteins are sequestered in a toxic β-sheet structure. However, PTM has protein- and residue-specific impact on protein aggregate formation. Panel B. hnRNPA1, FUS and TDP-43 can be target of several PTMs catalyzed by specific enzymes. hnRNP-A1 and FUS can be PARylated by PARPs and PARP1, respectively. FUS protein can be methylated by PRMT1 acetylated by CBP/p300 and NatA. Moreover, the Prion like domain of FUS is phosphorylated at multiple sites by the two kinases ATM and DNA-PK. TDP-43 is actively acetylated by CBP and phosphorylated by Casein Kinase. Finally, UBE2E and Parkin catalyze the ubiquitination of TDP-43.

References

    1. Aguzzi A., O'Connor T. (2010). Protein Aggregation Diseases: Pathogenicity and Therapeutic Perspectives. Nat. Rev. Drug Discov. 9, 237–248. 10.1038/nrd3050 - DOI - PubMed
    1. Alberti S., Halfmann R., King O., Kapila A., Lindquist S. (2009). A Systematic Survey Identifies Prions and Illuminates Sequence Features of Prionogenic Proteins. Cell 137, 146–158. 10.1016/j.cell.2009.02.044 - DOI - PMC - PubMed
    1. Arenas A., Chen J., Kuang L., Barnett K. R., Kasarskis E. J., Gal J., et al. (2020). Lysine Acetylation Regulates the RNA Binding, Subcellular Localization and Inclusion Formation of FUS. Hum. Mol. Genet. 29, 2684–2697. 10.1093/hmg/ddaa159 - DOI - PMC - PubMed
    1. Bedford M. T., Clarke S. G. (2009). Protein Arginine Methylation in Mammals: Who, what, and Why. Mol. Cell 33, 1–13. 10.1016/j.molcel.2008.12.013 - DOI - PMC - PubMed
    1. Blanc R. S., Richard S. (2017). Arginine Methylation: The Coming of Age. Mol. Cell 65, 8–24. 10.1016/j.molcel.2016.11.003 - DOI - PubMed